Stoke Therapeutics, Inc. (STOK)
NASDAQ: STOK · Real-Time Price · USD
34.65
+0.23 (0.67%)
At close: Mar 5, 2026, 4:00 PM EST
34.65
0.00 (0.00%)
After-hours: Mar 5, 2026, 4:20 PM EST
Stoke Therapeutics Stock Forecast
Stock Price Forecast
The 10 analysts with 12-month price forecasts for Stoke Therapeutics stock have an average target of 36.1, with a low estimate of 25 and a high estimate of 50. The average target predicts an increase of 4.18% from the current stock price of 34.65.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Stoke Therapeutics stock from 10 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 5 | 6 | 7 | 8 | 7 |
| Buy | 2 | 2 | 2 | 1 | 1 | 2 |
| Hold | 0 | 0 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 7 | 9 | 9 | 10 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wolfe Research | Wolfe Research | Buy Initiates $40 | Buy | Initiates | $40 | +15.44% | Feb 24, 2026 |
| Wedbush | Wedbush | Buy Maintains $32 → $36 | Buy | Maintains | $32 → $36 | +3.90% | Jan 12, 2026 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $24 → $35 | Strong Buy | Maintains | $24 → $35 | +1.01% | Jan 5, 2026 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $28 → $36 | Strong Buy | Maintains | $28 → $36 | +3.90% | Jan 5, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $35 → $50 | Strong Buy | Maintains | $35 → $50 | +44.30% | Dec 15, 2025 |
Financial Forecast
Revenue This Year
193.26M
from 36.56M
Increased by 428.68%
Revenue Next Year
35.57M
from 193.26M
Decreased by -81.59%
EPS This Year
0.19
from -1.65
EPS Next Year
-3.10
from 0.19
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 209.7M | 73.5M | ||||
| Avg | 193.3M | 35.6M | ||||
| Low | 179.3M | 11.8M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 473.6% | -62.0% | ||||
| Avg | 428.7% | -81.6% | ||||
| Low | 390.6% | -93.9% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 0.45 | -2.42 | ||||
| Avg | 0.19 | -3.10 | ||||
| Low | 0.03 | -3.58 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.